

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark OfficeAtty. Docket No.
MSK.P-035Serial No.
08/940,544ATPZL
TO
#4INFORMATION DISCLOSURE STATEMENT
BY APPLICANT
(Use several sheets if necessary)Applicant
Sadelain et al.Filing Date
September 30, 1997Group
RECEIVED

JUN - 3 1998

AUG 3 1998

U.S. PATENT DOCUMENTS

MATRIX CUSTOMER
SERVICE CENTER
Filing Date
if Appropriate

*Exam. Init..	Document No.	Date	Name	Class	Subclass	Filing Date if Appropriate
LQA	4 9 4 6 7 7 8	8/90	Ladner et al.	435	69.6	
LQA	5 4 0 5 9 9 0	4/95	Burke et al.	560	134	
LQA	4 6 7 5 2 8 7	6/87	Reisfeld et al.	435	1	
LQA	5 3 0 2 3 7 0	4/94	Neumeier et al.	424	1.53	
LQA	5 3 5 9 0 4 6	10/94	Capon et al.	536	23.4	

FOREIGN PATENT DOCUMENT

Document No.	Date	Country	Class	SubClass	Translation Yes No
9 7 3 4 6 3 4	9/97	WO	—	—	

OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)

LQA	Alvarez-Vallina et al., "Antigen-Specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors" <i>Eur. J. Immunol</i> 26: 2304-2309 (1996).
LQA	Feldhaus, et al., "A CD2/CD28 chimeric receptor triggers the CD28 signaling pathway in CTLL.2 cells", <i>Gene Therapy</i> 4: 833-838 (1997).

Examiner

Date Considered

12/6/99

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.